Table 1. Patient Characteristics.
| Characteristic | Patients, No. (%) | |
|---|---|---|
| 300 mg Twice Daily (n = 50) | 350 mg Twice Daily (n = 7) | |
| Age, median (range), y | 51 (30-72) | 51 (31-66) |
| Sex | ||
| Female | 50 (100) | 7 (100) |
| Race/ethnicity | ||
| White | 37 (74) | 6 (86) |
| Black/African American | 6 (12) | 0 |
| Asian | 6 (12) | 1 (14) |
| Unknown | 1 (2) | 0 |
| ECOG performance status | ||
| 0 | 20 (40) | 2 (29) |
| 1 | 30 (60) | 5 (71) |
| No. of previous HER2 agents, median (range) | 2 (1-3) | 1 (1-2) |
| Brain metastases | ||
| Yes | 30 (60) | 2 (29) |
| No | 20 (40) | 5 (71) |
| Most recent previous radiotherapy for brain metastases | ||
| Whole brain | 10 (20) | 2 (29) |
| Stereotactic radiosurgery | 9 (18) | 0 |
| None | 31 (62) | 5 (71) |
Abbreviation: ECOG, Eastern Cooperative Oncology Group.